Released Aug 5, 2015, after the close
10-Q filed Aug 5, 2015, 36 days after period end · 0001104659-15-056485
Q2 2015 · 10-Q
Revenue$329.00K$329.00K no prior Q2 2014 on fileno prior Q1 2015 on file
Net Income-$7.78M-$7.78M N/M vs Q2 2014N/M vs Q1 2015
EPS Diluted-$0.33-$0.33 N/M vs Q2 2014N/M vs Q1 2015
Operating Income-$7,218,000N/M
Operating Cash Flowderived$2,079,000N/M
Free Cash Flowderived$1,866,000N/M
Margins · derived
Operating margin-2193.9%
Net margin-2364.4%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2015 | Q2 2014 | Q2 2013 | Q2 2012 |
|---|---|---|---|---|
| Revenue | $329.00K | — | $290.00K | $1.08M |
| Net Income | -$7.78M | -$6.07M | -$5.53M | -$2.74M |
| EPS Diluted | -$0.33 | -$0.30 | -$4.46 | -$2.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR